Fig 1.
DEG analysis of ILC2s stimulated with (a) PGD2, (b) Δ12-PGD2, (c) Δ12-PGJ2, (d) 15-deoxy-Δ12,14-PGD2 and (e) 9α,11β-PGF2 versus unstimulated ILC2s. DEGs are highlighted in red for upregulated genes (adj. p-value ≤ 0.05, log2FC ≥ 0.58, BaseMean ≥ 5) and in blue for downregulated genes (adj. p-value ≤ 0.05, log2FC ≤ -0.58, BaseMean ≥ 5).
Fig 2.
DEG analysis of ILC2s incubated with fevipiprant versus ILC2s stimulated with (a) PGD2, (b) Δ12-PGD2, (c) Δ12-PGJ2, (d) 15-deoxy-Δ12,14-PGD2 and (e) 9α,11β-PGF2. DEGs are highlighted in red for upregulated genes (adj. p-value ≤ 0.05, log2FC ≥ 0.58, BaseMean ≥ 5) and in blue for downregulated genes (adj. p-value ≤ 0.05, log2FC ≤ -0.58, BaseMean ≥ 5).
Fig 3.
Gene set enrichment analysis with identified DEG (|log2FC| ≥ 0.58, adj. p-value ≤ 0.05) of metabolite activated ILC2s compared to unstimulated ILC2s (red = upregulated pathways, blue = downregulated pathways, increasing circle size corresponds to increasing significance).
Fig 4.
Gene set enrichment analysis with identified DEGs (|log2FC| ≥ 0.58, adj. p-value ≤ 0.05) of metabolite activated ILC2s pre-incubated with the selective DP2 antagonist fevipiprant compared to metabolite activated ILC2s without fevipiprant stimulation (red = upregulated pathways, blue = downregulated pathways, increasing circle size corresponds to increasing significance).